Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape. Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 15, 8, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively. Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 8 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 18 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 28 Amarantus Bioscience Holdings Inc 28 AnGes MG Inc 28 Angionetics Inc 29 Ascendia Pharmaceuticals LLC 29 AstraZeneca Plc 30 Athera Biotechnologies AB 30 Bayer AG 31 Biscayne Pharmaceuticals Inc 31 Capricor Therapeutics Inc 32 CardioVascular BioTherapeutics Inc 32 CSL Ltd 33 Gilead Sciences Inc 33 Human Stem Cells Institute 34 Idorsia Ltd 34 Juventas Therapeutics Inc 35 Lee's Pharmaceutical Holdings Ltd 35 LipimetiX Development Inc 36 Livzon Pharmaceutical Group Inc 36 Lonestar Heart Inc 37 MedImmune LLC 37 Merck & Co Inc 38 Nuo Therapeutics Inc 39 Pfizer Inc 39 Proteon Therapeutics Inc 40 Resverlogix Corp 40 Tasly Pharmaceutical Group Co Ltd 40 The Medicines Company 41 Verseon Corp 42 VESSL Therapeutics Ltd 42 ViroMed Co Ltd 43 XyloCor Therapeutics Inc 43 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 44 ACT-246475 - Drug Profile 44 AEM-28 - Drug Profile 45 AEM-2802 - Drug Profile 47 ALD-201 - Drug Profile 48 alferminogene tadenovec - Drug Profile 50 alprostadil - Drug Profile 55 AMRS-001 - Drug Profile 57 anacetrapib - Drug Profile 66 apabetalone - Drug Profile 69 APT-402 - Drug Profile 82 AZD-5069 - Drug Profile 83 AZD-5718 - Drug Profile 85 BAT-2094 - Drug Profile 86 beperminogene perplasmid - Drug Profile 87 BIS-5409 - Drug Profile 92 bivalirudin trifluoroacetate - Drug Profile 93 cangrelor tetrasodium - Drug Profile 94 CAP-1002 - Drug Profile 98 CAP-2003 - Drug Profile 105 clopidogrel bisulphate - Drug Profile 107 COR-2 - Drug Profile 108 Cryocell - Drug Profile 109 CSL-112 - Drug Profile 110 CVBT-141H - Drug Profile 112 dalcetrapib - Drug Profile 113 Gemacell - Drug Profile 117 JVS-100 - Drug Profile 118 MEDI-6012 - Drug Profile 123 MultiGeneAngio - Drug Profile 125 MZ-004 - Drug Profile 126 Neovasculgen - Drug Profile 128 PC-mAb - Drug Profile 129 PF-06282999 - Drug Profile 132 PMC-6 - Drug Profile 133 PR-15 - Drug Profile 134 Proteins for Ischemic Heart Disease - Drug Profile 136 ranolazine ER - Drug Profile 137 Recombinant Protein for Cardiovascular Diseases - Drug Profile 140 Rejuveinix - Drug Profile 141 rivaroxaban - Drug Profile 142 Small Molecules for Ischemic Heart Disease - Drug Profile 159 Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 160 Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 161 TSL-0202 - Drug Profile 163 vericiguat - Drug Profile 164 VM-202 - Drug Profile 166 vonapanitase - Drug Profile 170 XC-001 - Drug Profile 176 Xcel-hCardP - Drug Profile 177 Xcel-hCM - Drug Profile 178 ZK-001 - Drug Profile 179 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 181 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 185 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 187 Featured News & Press Releases 187 Appendix 197 Methodology 197 Coverage 197 Secondary Research 197 Primary Research 197 Expert Panel Validation 197 Contact Us 197 Disclaimer 198
List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Angionetics Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Idorsia Ltd, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Livzon Pharmaceutical Group Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pfizer Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by XyloCor Therapeutics Inc, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..2), H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..3), H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2017 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2017 (Contd..1), H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
